DOCSLIB.ORG

Pre Amendment 2 IONA Protocol Scotland

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pre Amendment 2 IONA Protocol Scotland Version 2 (Scotland) 25th April 2016 PROTOCOL (SCOTLAND) Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users. Short title – Identification Of Novel psychoActive substances (IONA) Chief Investigator Prof SHL Thomas Professor of Clinical Pharmacology and Therapeutics, Newcastle University Consultant Physician, Newcastle Hospitals NHS Foundation Trust (Royal Victoria Infirmary) Director, National Poisons Information Service (Newcastle) Unit. Address Medical Toxicology Centre, Wolfson Building, Newcastle University, Newcastle NE2 4HH Email [email protected] Tel 0191 222 8095 Sponsor Organisation - Newcastle Hospitals NHS Foundation Trust (R&D Ref 7312) Funding Organisation - National Institute for Health Research (Ref HPRU-2012-10076) IRAS References - 172425 (Scotland), 168706 (England and Wales), REC References Scotland A REC – 15/SS/0047 North East - Newcastle& North Tyneside 2 - 15/NE/0023 (England & Wales), Project website http://www.ncl.ac.uk/hpru/research/neuro/nps/ 1 Version 2 (Scotland) 25th April 2016 Co-investigators Newcastle Health Protection Research Unit, Newcastle University Dr Simon Hill NIHR Health Protection Research Unit Dr Mick Dunn Medical Toxicology Centre Prof Peter Blain Wolfson Building Dr Christopher M Morris Newcastle University Newcastle NE2 4HH Dr Alasdair Blain School of Biology Prof Steven Rushton Newcastle University Newcastle NHS Toxicology Laboratories Dr Nigel Brown Wansbeck Hospital Toxicology Laboratory Northumbria Hospitals NHS Foundation Trust. Clinical Chemistry / Toxicology, Woodhorn Lane, Ashington, Northumberland NE63 9JJ Dr Jonathan Berg Toxicology Laboratory, Clinical Dr Loretta Ford Biochemistry, City Hospital, Sandwell and West Birmingham NHS Foundation Trust Dudley Road, Birmingham, B18 7QH Dr Alun Hutchings Cardiff Toxicology Laboratories The Academic Centre University Hospital Llandough Penarth, Vale of Glamorgan, CF64 2XX National Poisons Information Service Prof Michael Eddleston National Poisons Information Service, Dr Jonathan Wraight Edinburgh Unit, Royal Infirmary of Dr James Dear Edinburgh, QMRI, E3.20 47 Little France Cresc Edinburgh, EH16 4TJ Dr John Thompson National Poisons Information Service, Cardiff Unit, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XW 2 Version 2 (Scotland) 25th April 2016 Prof Allister Vale National Poisons Information Service, Dr Sally Bradberry Birmingham Unit, City Hospital, Birmingham B187QH NHS Emergency Departments Names Departments Dr Simon Hill Newcastle Hospitals NHS Foundation Trust Dr John Wright Royal Victoria Infirmary, Queen Victoria Road, Newcastle NE1 4LP Prof Michael Eddleston NHS Lothian Dr Jonathan Wraight Royal Infirmary of Edinburgh Dr James Dear QMRI, E3.20, 47 Little France Crescent Edinburgh, EH16 4TJ Dr Paul Dargan Guy's and St Thomas' NHS Foundation Trust and King's Dr David M Wood Health Partners Clinical Toxicology, 3rd Floor, Block C, South Wing, St Thomas' Hospital, London SE1 7EH Dr John Thompson Cardiff and Vale University Health Board Dr James Coulson University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XW Dr Johann Grundlingh Barts and the London NHS Foundation Trust Emergency Department, Acute and Family Division Royal London Hospital, Whitechapel London E1 1BB Dr Tim Nutbeam Plymouth Hospitals NHS Trust Emergency Department, Derriford Hospital Plymouth PL6 8DH Dr Mike Aisbit Southport and Omskirk Hospital NHS Trust, Southport and Formby District General Hospital Town Lane, Kew, Southport, Merseyside, PR8 6PN Dr Ashraf Kamour Pennine Acute Hospitals NHS Trust North Manchester General Hospital, Delaunays Road, Crumpsall Manchester M8 5RB Fairfield General Hospital, Rochdale Old Road, Bury, BL9 7TD; North Manchester General Hospital, Delaunays Road, 3 Version 2 (Scotland) 25th April 2016 Crumpsall, Manchester, M8 5RB Dr Paul Acheampong Royal Liverpool and Broadgreen University Hospitals NHS Trust Royal Liverpool University Hospital, Prescot Street Liverpool L7 8XP Mr Simon Tucker Blackpool Teaching Hospitals NHS Foundation Trust Blackpool Victoria Hospital, Whinney Heys Road Blackpool FY3 8NR Dr Heather Jarman St George’s University Hospitals NHS Foundation Trust Blackshaw Road, Tooting, London SW17 0QT Dr Nigel Brown Northumbria Hospitals NHS Foundation Trust, Wansbeck General Hospital, Woodhorn Lane , Ashington, Northumberland, NE63 9JJ Further departments and local PIs to be confirmed Start date 9th November 2015 End date 1st April 2019 Duration 41 months 4 Version 2 (Scotland) 25th April 2016 TABLE OF CONTENTS Co-investigators........................................................................................................................................... 2 TABLE OF CONTENTS ........................................................................................................................... 5 ABBREVIATIONS ..................................................................................................................................... 6 SUMMARY ................................................................................................................................................. 8 INTRODUCTION ..................................................................................................................................... 10 Novel Psychoactive Substances ............................................................................................................ 10 Drug control in the UK ......................................................................................................................... 12 Research in progress ............................................................................................................................. 13 Research gaps ........................................................................................................................................ 14 AIMS AND OBJECTIVES ...................................................................................................................... 16 METHODS ................................................................................................................................................ 17 Type of study .......................................................................................................................................... 17 Participants ............................................................................................................................................ 17 Research methods .................................................................................................................................. 18 Study 1. Analysis of NPIS enquiry data ........................................................................................... 18 Study 2. Collation of toxicology data provided by participating NHS laboratories .................... 20 Study 3. Further analysis of samples already collected as part of clinical care. .......................... 22 Study 4. Collection of samples for research purposes from people attending participating emergency departments .................................................................................................................... 25 Confidentiality and data protection ..................................................................................................... 35 Statistical aspects ................................................................................................................................... 37 Research approvals ............................................................................................................................... 38 Analytical methods ................................................................................................................................ 39 Mathematical and modelling methods................................................................................................. 40 Dissemination of research results ........................................................................................................ 41 REFERENCES .......................................................................................................................................... 42 APPENDIX 1: Classification of NPS and related traditional recreational drugs ............................... 47 APPENDIX 2: Clinical data collected (Study 4) .................................................................................... 48 APPENDIX 3: Substances included in Newcastle recreational drug and NPS screen and standards available (as of January 2015).................................................................................................................. 53 5 Version 2 (Scotland) 25th April 2016 ABBREVIATIONS 25I-NBOMe 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine 2-AI, 2-aminoindan 2C-B 2,5-dimethoxy-4-bromophenethylamine 2C-E 2,5-dimethoxy-4-ethylphenethylamine 5-IAI 5-Iodo-2-aminoindane 5-IT 5-(2-Aminopropyl)indole ACMD Advisory Council on the Misuse of Drugs ALT Alanine transaminase AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) AMT alphamethyltryptamine APB aminopropylbenzofuran APICA 1-Amino-5-phosphonoindan-1-carboxylic acid AST Aspartate transaminase BB-22 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester BZP Benzylpiperazine CK Creatine kinase D2PM Diphenylprolinol DEWS Drugs
Load more

Recommended publications
  • How Pre-Clinical Studies Have Influenced Novel Psychoactive Substance Legislation in the UK and Europe
    Article How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe Santos, Raquel, Guirguis, Amira and Davidson, Colin Available at http://clok.uclan.ac.uk/31793/ Santos, Raquel ORCID: 0000-0003-3129-6732, Guirguis, Amira and Davidson, Colin ORCID: 0000-0002-8180-7943 (2020) How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe. British Journal Of Clinical Pharmacology, 86 (3). pp. 452-481. ISSN 0306-5251 It is advisable to refer to the publisher’s version if you intend to cite from the work. http://dx.doi.org/10.1111/bcp.14224 For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>. For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/ All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the policies page. CLoK Central Lancashire online Knowledge www.clok.uclan.ac.uk How Pre-Clinical Studies Have Influenced Novel Psychoactive Substance Legislation in The UK and Europe Raquel Santos1, Amira Guirguis2 & Colin Davidson1* 1School of Pharmacy & Biomedical Sciences, Faculty of Clinical & Biomedical Sciences, University of Central Lancashire, UK. 2Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, Wales, UK. *Corresponding author Colin Davidson School of Pharmacy and Biomedical Science Faculty of Clinical & Biomedical Sciences University of Central Lancashire Preston PR1 2HE +44 (0)1772 89 3920 [email protected] Key words: novel psychoactive substance, legal high, legislation, toxicity, abuse Running Head: review of NPS pharmacology The authors have no conflicts of interest to declare Page | 1 Abstract Novel psychoactive substances (NPS) are new drugs of abuse.
    [Show full text]
  • Overview of the Misuse of Drugs Act 1971
    Psychoactive Substances Bill Factsheet: Overview of the Misuse of Drugs Act 1971 1. The provisions of the Psychoactive Substances Bill will build on and complement the existing legislative framework for the control of dangerous drugs as contained in the Misuse of Drugs Act 1971 (the 1971 Act). This factsheet provides an overview of the provisions of the 1971 Act. The Misuse of Drugs Act 1971 2. The 1971 Act provides the legislative framework for the regulation of “dangerous or otherwise harmful” drugs; the Act applies to the whole of the United Kingdom. The 1971 Act implements the UK’s international obligations under the United Nations Conventions for the prevention of drug misuse and trafficking, namely the Single Convention on Narcotic Drugs 19611 and the Convention on Psychotropic Substances 19712, which are complemented by the Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 19883. 3. The 1971 Act applies to "controlled drugs". This includes substances or products specified in Schedule 2 to the Act. That Schedule divides controlled drugs into one of three Classes – A, B and C – broadly based on their relative harms, with Class A drugs considered the most harmful. Examples of each class of drug are: Class A - cocaine, methadone and opium; Class B - amphetamine, cannabis and ketamine; Class C - khat and temazepam. In addition, controlled drugs include any substance or product specified in a temporary class drug order as a drug subject to temporary control (see below). 4. The 1971 Act provides for a range of offences in relation to controlled drugs, including: • importation and exportation (section 3); • production, supply or offering to supply (section 4); • possession and possession with intent to supply (section 5); and • permitting premises to be used for certain activities, including the production or supply of a controlled drug and smoking cannabis (section 8).
    [Show full text]
  • Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
    PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
    [Show full text]
  • Temporary Class Drug Order Report: 5-6APB and Nbome Compounds
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0555 [email protected] Home Secretary Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 29 May 2013 Dear Home Secretary, I am writing to formally request that you consider laying a temporary class drug order (TCDO) pursuant to section 2A of the Misuse of Drugs Act 1971 on the following two groups of novel psychoactive substances (NPS). We consider the laying of TCDOs is appropriate as a pre-emptive measure in advance of the summer music festival season. Both classes of drugs have been associated with serious harm and drug-related deaths. ‘Benzofury’ compounds 5- and 6-APB and related substances are phenethylamine-type materials, related to ecstasy (MDMA). There have been several deaths and hospitalisations in the UK associated with these NPS, although poly-substance use often complicates the case. Research indicates that there is a potential risk of cardiac toxicity associated with the long-term use of 5- and 6-APB. Anecdotal user reports suggest that the consumption of these substances can cause insomnia, increased heart rate and anxiety, with some users reporting MDMA like symptoms. The related compound 5-IT has been subject to an EMCDDA-Europol joint report and an EMCDDA risk assessment exercise. [www.emcdda.europa.eu/publications/joint-reports/5- IT] 1 The substances recommended for control are: 5- and 6-APB: (1-(benzofuran-5-yl)-propan-2-amine and 1-(benzofuran-6-yl)-propan- 2-amine) and their N-methyl derivatives.
    [Show full text]
  • Soccer & Society, Vol
    Hay, Roy and McDonald, Heath 2007, A victory for the fans? Melbourne's new football club in recent historical perspective, Soccer & society, vol. 8, no. 2/3, pp. 298-315. This is the postprint version. This is an Accepted Manuscript of an article published by Taylor & Francis in Soccer & society in 2007, available at: http://www.tandfonline.com/10.1080/14660970701224558 ©2007, Taylor & Francis Reproduced by Deakin University with the kind permission of the copyright owner. Available from Deakin Research Online: http://hdl.handle.net/10536/DRO/DU:30007257 A Victory for the fans? Melbourne’s new football club in recent historical perspective.1 Roy Hay and Heath McDonald © Sports and Editorial Services Australia and Deakin University In 2005 a completely new football (soccer) team, the Melbourne Victory, was created in Victoria, Australia to play in a new national league, the A-League.2 Within a year it was drawing more than 50 000 fans to a regular season home game against Sydney FC in a league whose eight participants stretch from Perth, Western Australia to Auckland in New Zealand.3 This was the third time in less than a decade that a new soccer team had been launched in a city which is best known for its devotion to Australian Rules football, cricket and horse racing.4 The other two, Collingwood Warriors and Carlton, lasted one season and three seasons and eight games respectively before collapsing in acrimony and debt. Collingwood and Carlton began with on-field success. Collingwood won the National Soccer League (NSL) cup in 1996–67,
    [Show full text]
  • CREW Booklet
    PSYCHOACTIVE DRUGS V2.1 12/16 SERVICE AVAILABILITY Drop-in Monday – Wednesday: 1pm – 5pm Thursday: 3pm – 7pm Friday – Saturday: 1pm – 5pm Sunday: Closed Telephone information Monday – Friday: 10am – 5pm Online information: www.mycrew.org.uk CONTACT Address | 32 Cockburn Street, Edinburgh, EH1 1PB Telephone | 0131 220 3404 Email | [email protected] Main | www.crew2000.org.uk Enterprise | www.mindaltering.co.uk Info and support | www.mycrew.org.uk Facebook | www.facebook.com/Crew2000 Twitter | www.twitter.com/Crew_2000 Instagram | www.instagram.com/Crew_2000 Psychoactive drugs have mind altering properties. They are often consumed to produce a wide range of desirable physical and psychological effects and there are hundreds of substances available. Psychoactive drugs can occur naturally (e.g. cannabis and psilocybin); be extracted from natural sources (e.g. cocaine and heroin) or produced synthetically (man-made) in a laboratory (e.g. MDMA and methamphetamine). People choose to take drugs for many reasons including relaxation, insomnia, pain relief, escapism, peer pressure and social norms, to get high, self-medication, to have fun, to lower inhibitions, to feel different, because they want to, to increase connection with others and music, to increase creativity, increase sexual arousal, curiosity, tradition, religious or spiritual beliefs, to lose/gain weight, to cope with grief, loneliness, trauma etc. People from all strata of society have the potential to consume drugs and we must avoid stereotypes. Most drug use is recreational and not recorded; however, pockets of problematic use exist in a range of settings. The use of drugs is widespread and includes not just illegal substances but alcohol, nicotine, caffeine and medicines - which many people do not consider to be drugs.
    [Show full text]
  • Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3Rd Floor Seacole Building 2
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor Seacole Building 2. Marsham Street London SW1P 4DF 020 7035 0454 Email: [email protected] Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 18th October 2012 Dear Home Secretary, In March 2012 the ACMD advised that methoxetamine be subject to a temporary class drug order. Methoxetamine was marketed as a legal alternative to ketamine until a temporary class drug order was implemented in April 2012. As is now required, the ACMD has followed its initial assessment with a consideration of methoxetamine in the context of the Misuse of Drugs Act 1971; I enclose the report with this letter. The chemical structure of methoxetamine bears a close resemblance to that of both ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well- documented and serious adverse effects following both acute and chronic usage. Users report that the effects of methoxetamine are similar to those of ketamine, however, some users report that the effects are of longer duration.The harmful effects reported include severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant hallucinations. The first analytically confirmed series reported by Guy‟s and St Thomas‟ NHS Foundation Trust, London in 2011, was of three individuals who presented having self-reported use of methoxetamine. All three presented with a ketamine-like dissociative state, but also had significant stimulant effects with agitation and cardiovascular effects including tachycardia and hypertension. Toxicological screening of serum samples confirmed methoxetamine use in two of the cases.
    [Show full text]
  • CREW NPS Booklet
    NEW Psychoactive DRUGS V1.7 05/15 Service availability Drop-in: Monday – Wednesday: 1pm – 5pm, Thursday: 3pm – 7pm, Friday – Saturday: 1pm – 5pm, Sunday: Closed Telephone information and support: Monday – Friday: 10am – 5pm Online information and chatroom support: www.mycrew.org.uk Address | 32 Cockburn Street | Edinburgh | EH1 1PB Telephone | 0131 220 3404 Email | [email protected] Main | www.crew2000.org.uk Enterprise | www.mindaltering.co.uk Info and support | www.mycrew.org.uk Facebook | www.facebook.com/Crew2000 Twitter | www.twitter.com/Crew_2000 Instagram | www.instagram.com/Crew_2000 This booklet has been designed to expand worker knowledge and confidence in the area of NPS. It is most useful when discussed as part of Crew’s NPS training. Crew was established in 1992, in response to the rapid expansion of recreational drug use. We provide up-to-date information on the drugs that people are taking so they can make informed decisions about their own health. This is achieved using a stepped care approach and through collaboration with volunteers, service users and professionals. Crew neither condemns nor condones drug use, but we believe there are ways to reduce harm to health. As a national agency, Crew is at the forefront of emerging drug trends and we engage at all levels including service development, practice and policy. Our services include: – Support line: non-judgmental drug and sexual health information and support. – Drop-in: drug and sexual health information, condoms (NHS c:card service) and DJ workshops. – Outreach services: we provide welfare at large events, such as clubs and festivals to educate revellers on partying safely.
    [Show full text]
  • YONGSTOWN STATE UNIVERSITY ORAL HISTORY PROGRAM World
    YONGSTOWN STATE UNIVERSITY ORAL HISTORY PROGRAM World War I1 Personal Experiences O.H. 1816 David Simerlink Interviewed By Elaine Fowler On June 1 1,1996 David J. Simerlink David Simerlink was born in Youngstown, Ohio, September 25, 1923. He attended James Hillman Junior High and Garfield High School. David joined the U.S. Navy Reserves in 1940. He was discharged from the Navy in 1946. While home on leave in Youngstown he married Rita Simerlink on June 25, 1945. After the war he returned to Youngstown. Rita and David have four children, David - 50, Richard - 48, Thomas - 4 1, and Ronald - 39. David was employed by the Youngstown Water Department for ten years, 1970- 1980. He retired in 1980. Simerlink is a member of the St. Nicholas. He is also associated with the AMVETS. He had been a Boy Scout, Cub Scouts, and Explorer leader. His special interests are cutting stamps for the vets and woodworking. Youngstown State University Oral History Department World War I1 O.H. # 1816 Interviewee: DAVID J. SIMERLINK Interviewer: Elaine Fowler Subject: World War II Date: June 11, 1996 EF: David Simerlink at 1917 Lynn Ave in Youngstown, Ohio for the Youngstown State University Oral History Program by Elaine Fowler at approximately 9:27am. Mr. Simerlink? DS: Simerlink, yes. EF: What do you remember about your parents? DS: My parents they were hard workers. My dad worked in the steel mill and my mother was a hard worker. We had, there were seven boys at our house, I have six brothers and my grandmother lived with us.
    [Show full text]
  • A Chemical Analysis Examining the Pharmacology of Novel Psychoactive Substances Freely Available Over the Internet and Their Impact on Public (Ill) Health
    Open Access Research A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public (ill) health. Legal highs or illegal highs? Tammy C Ayres,1,2 John W Bond3 To cite: Ayres TC, Bond JW. ABSTRACT ARTICLE SUMMARY A chemical analysis Objectives: Public Health England aims to improve the examining the pharmacology nation’s health and acknowledges that unhealthy Article focus of novel psychoactive lifestyles, which include drug use, undermine society’s - substances freely available To analyse the chemical composition of health and well-being. Recreational drug use has over the internet and their substances bought over the internet, including impact on public (ill)health. changed to include a range of substances sold as the legality of the active ingredients and if Legal highs or illegal highs? ‘research chemicals’ but known by users as ‘legal highs’ products differ between retailers. BMJ Open 2012;2:e000977. (legal alternatives to the most popular illicit recreational - To consider the medical implications and adverse doi:10.1136/ drugs), which are of an unknown toxicity to humans and health risks associated with legal highs bought bmjopen-2012-000977 often include prohibited substances controlled under the over the internet. Misuse of Drugs Act (1971). Consequently, the long- term effects on users’ health and inconsistent, often Key messages < Prepublication history for illegal ingredients, mean that this group of drugs - The most recent examination of the composition this paper is available online. presents a serious risk to public health both now and in of ‘legal highs’, conducted 6 months after the To view these files please the future.
    [Show full text]
  • Methiopropamine (MPA) Critical Review Report Agenda Item 4.8
    Methiopropamine (MPA) Critical Review Report Agenda Item 4.8 Expert Committee on Drug Dependence Thirty-eighth Meeting Geneva, 14-18 November 2016 38th ECDD (2016) Agenda item 4.8 MPA Page 2 of 21 38th ECDD (2016) Agenda item 4.8 MPA Contents Acknowledgements .......................................................................................................................... 5 Summary .......................................................................................................................................... 6 1. Substance identification .................................................................................................... 7 A. International Nonproprietary Name (INN) ........................................................................ 7 B. Chemical Abstract Service (CAS) Registry Number .......................................................... 7 C. Other Chemical Names ...................................................................................................... 7 D. Trade Names ...................................................................................................................... 7 E. Street Names ...................................................................................................................... 7 F. Physical Appearance .......................................................................................................... 7 G. WHO Review History ......................................................................................................... 7 2.
    [Show full text]
  • Next Generation of Novel Psychoactive Substances on the Horizon – A
    Drug and Alcohol Dependence 157 (2015) 1–17 Contents lists available at ScienceDirect Drug and Alcohol Dependence j ournal homepage: www.elsevier.com/locate/drugalcdep Review Next generation of novel psychoactive substances on the horizon – A complex problem to face ∗ Jolanta B. Zawilska , Dariusz Andrzejczak Department of Pharmacodynamics, Medical University of Lodz, Poland a r t i c l e i n f o a b s t r a c t Article history: Background: The last decade has seen a rapid and continuous growth in the availability and use of novel Received 14 May 2015 psychoactive substances (NPS) across the world. Although various products are labeled with warnings Received in revised form “not for human consumption”, they are intended to mimic psychoactive effects of illicit drugs of abuse. 30 September 2015 Once some compounds become regulated, new analogues appear in order to satisfy consumers’ demands Accepted 30 September 2015 and at the same time to avoid criminalization. This review presents updated information on the second Available online 9 October 2015 generation of NPS, introduced as replacements of the already banned substances from this class, focusing on their pharmacological properties and metabolism, routes of administration, and effects in humans. Keywords: Methods: Literature search, covering years 2013–2015, was performed using the following keywords Novel psychoactive substances alone or in combination: “novel psychoactive substances”, “cathinones”, “synthetic cannabinoids”, Synthetic cannabimimetics Cathinones “benzofurans”, “phenethylamines”, “2C-drugs”, “NBOMe”, “methoxetamine”, “opioids”, “toxicity”, and Psychostimulants “metabolism”. NBOMe compounds Results: More than 400 NPS have been reported in Europe, with 255 detected in 2012–2014. The most Methoxetamine popular are synthetic cannabimimetics and psychostimulant cathinones; use of psychedelics and opioids Psychedelics is less common.
    [Show full text]